Sihuan Pharmaceutical Holdings Group Ltd.

Equities

460

BMG8162K1137

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
0.53 HKD -7.02% Intraday chart for Sihuan Pharmaceutical Holdings Group Ltd. -8.62% -18.46%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China MT
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3% MT
China Grants Registration Approval to Sihuan Pharmaceutical's Insulin Products MT
Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes CI
China's Medical Products Administrator Approves Sihuan Pharma Unit's Diabetes Drug MT
National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical CI
China Accepts New Drug Application of Sihuan Pharmaceutical Subsidiary's Breast Cancer Treatment MT
China Accepts New Drug Application for Sihuan Pharmaceutical Unit's Breast Cancer Tablets MT
Sihuan Pharmaceutical Swings to H1 Loss MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sihuan Pharmaceutical's Revenue to Drop 30% in H1 MT
Sihuan Pharmaceutical Holdings Group Ltd. Provides Unaudited Consolidated Guidance for the Six Months Ended 30 June 2023 CI
China Approves Sihuan Unit's Clinical Trial for Diabetes Injections; Shares Fall 3% MT
Sihuan Pharma to Conduct Clinical Trials of Diabetes Injection MT
Sihuan Pharma Unit Gets Nod to Test Diabetes Drug MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial CI
China Approves Sihuan Pharmaceutical Unit's Phase 2 Trial for Metastatic Prostate Cancer Treatment MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China CI
Sihuan Pharma Unit Gets Nod for Marketing of Ulcer Drug MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Change of Principal Place of Business in Hong Kong CI
China Grants Investigational Drug Nod to Sihuan Unit's Injectable for Diabetics MT
Sihuan Pharmaceutical Buys Back 4.5 Million Shares MT
Chart Sihuan Pharmaceutical Holdings Group Ltd.
More charts
Sihuan Pharmaceutical Holding Group Ltd. is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company is mainly engaged in the research and development, manufacture and sales of pharmaceutical products in China. Its products are applicable in cardio-cerebral vascular (CCV) system, central nervous system, metabolism, oncology and anti-infective fields. Its CCV products include Kelinao, Anjieli and Oudimei, among others. Its non-CCV products include Ren’Ao, Metronidazole and Clindamycin, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.57
Average target price
-
Consensus

Annual profits - Rate of surprise